{"filing":{"accession_number":"0001104659-26-091188","cik":"0001512762","ticker":"CHRS","company_name":"Coherus Oncology, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"chrs-20260805x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/chrs-20260805x8k.htm"},"events":[{"id":24142,"run_id":21852,"accession_number":"0001104659-26-091188","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Conditions). The press release discloses net revenue of $14.3 million for Q2 2026 (up from $10.3 million in Q2 2025), net loss from continuing operations of $33.3 million (improved from $44.9 million in Q2 2025), and detailed financial statements including condensed consolidated statements of operations and balance sheets. The filing includes LOQTORZI revenue growth metrics, pipeline updates, and cash position information material to investors.","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":24563,"accession_number":"0001104659-26-091188","item_number":"2.02","item_title":"Results of Operations and Financial Conditions.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Conditions). The press release discloses net revenue of $14.3 million for Q2 2026 (up from $10.3 million in Q2 2025), net loss from continuing operations of $33.3 million (improved from $44.9 million in Q2 2025), and detailed financial statements including condensed consolidated statements of operations and balance sheets. The filing includes LOQTORZI revenue growth metrics, pipeline updates, and cash position information material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:19:21.490524+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24563,"accession_number":"0001104659-26-091188","item_number":"2.02","item_title":"Results of Operations and Financial Conditions.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Conditions). The press release discloses net revenue of $14.3 million for Q2 2026 (up from $10.3 million in Q2 2025), net loss from continuing operations of $33.3 million (improved from $44.9 million in Q2 2025), and detailed financial statements including condensed consolidated statements of operations and balance sheets. The filing includes LOQTORZI revenue growth metrics, pipeline updates, and cash position information material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:19:21.490524+00:00","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-08-05"}]}